Table 1.
Variable | n | % | ||
---|---|---|---|---|
Total number of test drug-comparator pairs observed | 194 | 100 | ||
Endpoint | HDRS | 19 | 10 | |
PANSS | 12 | 6 | ||
PEF | 16 | 8 | ||
Blood pressure | 41 | 21 | ||
HbA1c | 24 | 12 | ||
CGI-I | Depression | 33 | 17 | |
Schizophrenia | 25 | 13 | ||
Asthma | 24 | 12 | ||
Comparator | Placebo | 44 | 23 | |
Active | 150 | 77 | ||
Statistical purpose | Superiority | 32 | 17 | |
Non-inferiority and equivalence | 57 | 29 | ||
Dose response | 20 | 10 | ||
Other | 85 | 44 | ||
Number of arms | 2 | 142 | 73 | |
3 | 28 | 14 | ||
4 | 22 | 11 | ||
5 | 2 | 1 | ||
All | 194 | 2.40 (0.729)a | ||
Sample size | 194 | 236 (108)a | ||
Length of trial (weeks) | 194 | 8.54 (4.10)a | ||
Mean number of subjects per site | 182 | 5.14 (3.20)a | ||
Approval year | 194 | 1999b | ||
Dosing schedule | Flexible | 109 | 56 | |
Fixed | 85 | 44 | ||
Type of endpoint | Subjective endpoint (assessment score) | 30 | 15 | |
Subjective endpoint | 84 | 43 | ||
(Clinical Global Improvement) | ||||
Objective endpoint | 80 | 41 | ||
Primary endpoint | ||||
Yes | 147 | 76 | ||
No | 47 | 24 | ||
Comparator with the same mode of action of the test drug | ||||
Yes | 153 | 79 | ||
No | 41 | 21 | ||
Phase2 | ||||
Yes | 36 | 19 | ||
No | 158 | 81 | ||
Precedent foreign clinical trial data | ||||
Yes | 83 | 43 | ||
No | 111 | 57 | ||
Companies' domestic development experience with similar drugs | ||||
Yes | 91 | 47 | ||
No | 103 | 53 | ||
Mean age of subjects | 193 | 48.0 (7.63)a | ||
Ratio of female subjects | 194 | 0.47 (0.10)a | ||
Effect size | Placebo | 44 | 0.58 (0.52)a | |
Active | 150 | 0.08 (0.22)a |
aMean (SD), bMedian.
Precedent foreign clinical data: a dummy variable that was assigned a value of 1 if foreign clinical trials were included in the clinical data package. Companies’ domestic development experience with similar drugs: a dummy variable that was assigned a value of 1 when a company had gained at least one drug approval for the same therapeutic indication in Japan before the approval of a drug we analyzed.
HDRS: the Hamilton Depression Rating Scale for depression, PNASS: Positive and Negative Syndrome Scale for schizophrenia, PEF: morning Peak Expiratory Flow for asthma, Blood pressure: diastolic pressure for hypertension, HbA1c: hemoglobin A1c for diabetes, CGI-I: Clinical Global Impression of Improvement.